Turnaround in Place at Cochlear
Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read MoreBiotechnology
COVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read MoreNoxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates
Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company’s CEO Dr Graham Kelly tells us more.
Read MoreRobotics and A.I.: Defeating COVID-19
Alex Cook from BetaShares examines the role robotics and A.I. have played not only in developing a vaccine but also in its distribution.
Read MoreGrowth For ResMed Despite Challenges
Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.
Read MoreAntisense Therapeutics – Price Target Raised from $0.305 to $0.43
Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read MoreImmutep: fighting the good fight
In this video, immunotherapy pioneer Immutep’s (ASX: IMM) CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments.
Read MoreWhat’s next for Antisense Therapeutics?
Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.
Read MoreCOVID-19 Sees Buffett Dive Into Pharma
With the COVID-19 pandemic dominating markets, politics, and everyday life, it’s no wonder that Warren Buffett has moved heavily into pharma and medical stocks in the quarterly latest fund manager filing with the US Securities and Exchange Commission.
Read MoreA potential turning point in the battle against COVID-19
Pfizer and BioNTech have announced preliminary data from a late-stage clinical trial for their COVID-19 vaccine candidate, and the results were better than expected. Matt Peron and Andy Acker from Janus Henderson Investors explain what this means for the fight to end the pandemic and the next leg of the market cycle.
Read MoreAustralian Healthcare: 10 Years In 10 Charts
With Alphinity celebrating its 10th anniversary we have explored what has happened in the healthcare sector in the decade since Alphinity was first established.
Read MoreAntisense Eyes A Golden Ticket In The US
Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read MoreMesoblast, COVID-19 And Trump?
As an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.
Read MoreUnderstanding Biotechs Starts With Understanding How Drugs Are Named?
Drugs and biologics often end up with multiple names as they travel through the development and commercialisation. It can all get very confusing and even more so after the therapeutic is on the market but turns out to have multiple different names across multiple different jurisdictions.
Read More